AgomAb Therapeutics NV (NASDAQ:AGMB) Given Consensus Recommendation of “Moderate Buy” by Analysts

AgomAb Therapeutics NV (NASDAQ:AGMB) has received an average rating of “Moderate Buy” from the five brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $32.00.

A number of brokerages recently weighed in on AGMB. HC Wainwright began coverage on AgomAb Therapeutics in a research note on Monday. They issued a “buy” rating on the stock. Leerink Partners initiated coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 target price on the stock. Zacks Research raised AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. JPMorgan Chase & Co. initiated coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 target price on the stock. Finally, Morgan Stanley initiated coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 target price on the stock.

AgomAb Therapeutics Stock Performance

Shares of AGMB opened at $10.98 on Monday. The business has a 50-day moving average of $10.96. AgomAb Therapeutics has a 1-year low of $8.75 and a 1-year high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.